Recipharm Presents its Seventh International Environmental Award Winner
Recipharm is pleased to announce that its seventh International Environmental Award has been awarded to Dr Ettore Zuccato, head of the Laboratory of Food Toxicology, Department of Environmental Health Sciences at Mario Negri Institute for Pharmacological Research (Milan, Italy), in recognition of his longstanding work as an outstanding scientist, resulting in identification, quantification and monitoring levels of environmental contamination from pharmaceuticals.
The purpose of the Recipharm International Environmental Award is to encourage and inspire best practice and innovation to promote good examples and to encourage environmental dialog within the pharmaceutical industry. The prize is awarded annually by Recipharm to the best environmental performance or environmental best practice and innovation by the academic community or pharmaceutical industry. Since Recipharm was founded in 1995, its commitment to environmental best practice has been a pivotal corporate mission.
Dr Ettore Zuccato is internationally recognized as a leading scientist in the field of emerging environmental contaminants, with a specialist focus on pharmaceuticals and illicit drugs in surface waters. He has conducted pioneering research, together with other prominent scientists, on quantifying the occurrence of pharmaceuticals in the Italian aquatic environment, with the study results published in “The Lancet”, fuelling global concern about the potential environmental impact that pharmaceuticals can have.
His group carried out multiple studies in waste water including identifying pharmaceutical pollutants prevalent in Northern Italy, and validating an analytical method that simultaneously determines pharmaceuticals of various therapeutic categories present in waste water. Furthermore, he initiated research into the presence of pharmaceuticals and their metabolites in Italian rivers, sewage treatment plants and drinking water samples, characterising contamination and assessing related risks.
Lars Backsell, Chairman of the board of Recipharm, commented: “Recipharm is deeply honoured to award this accolade to Dr Ettore Zuccato. Indeed, he is one the foremost authorities and leaders in the field of environmental contamination by pharmaceuticals. His authoritative research, which has been published extensively across world leading scientific journals, has provided a comprehensive view in this critical subject area.”
He continued: “Moreover, one important focus of his research is the need for proper evaluation of the multiple possibilities offered by new technologies to improve pharmaceuticals to mitigate the adverse environmental consequences of widespread environmental contamination.”
Commenting on winning the award, Dr Ettore Zuccato remarked: “I take great pride in being granted this award from Recipharm. I, together with other scientific experts and researchers, have devoted long years of research into harm caused to the environment and to drawing attention to the contamination concerned, how it can be best identified, assessed and monitored and how improvements can be made to reduce the levels.”
He added: “I look forward to continuing my studies in the certain knowledge that prominent organisations in the pharma industry, like Recipharm are taking an active interest in environmental contamination, and furthering the drive to heighten awareness and change matters for the better, through this type of accolade.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.